StockGuru Blog: SKVI’s recent exclusive licensing agreement with RHEI creates the opportunity for Skinvisible to be profitable in 2010

Skinvisible, Inc. (OTCBB:SKVI) StockGuru SKVI Profile

SKVI’s recent exclusive licensing agreement with RHEI creates the opportunity for Skinvisible to be profitable in 2010.

This represents a HUGE milestone for ANY pharmaceutical company. The potential for SKVI at this point is tremendous and they find themselves at an inflection point. This is the time to be in SKVI.

The RHEI exclusive licensing agreement for $1.5M in Licensing Fees will be paid in milestones from an incredibly solid firm with business in Europe and CHINA: RHEI which is a Hong Kong based pharmaceutical company. The licensing agreement is in addition to ongoing royalties SKVI will receive from the sales of their licensed products. This creates two significant revenue streams for SKVI.

The RHEI agreement is supported by the all important patent recently issued in Hong Kong.

The timing of the RHEI Agreement (RHEI is a Hong Kong based pharmaceutical company) is clearly opportune and NOT BY ACCIDENT. You have the Hong Kong patents being issues simultaneously with the RHEI agreement. Management is working hard here and the shareholders are the clear beneficiaries.

The two new agreements with RHEI represent $1.5 million in licensing fees and – additional – on-going royalties on product sales for Skinvisible. Pursuant to this agreement RHEI will launch the three SKVI products once a manufacturer is located in the applicable regions.

What this means is that SKVI which has a overhead of less than $100,000 a month has the potential to be cash flow positive for the balance of the year.

When you couple this with royalty and polymer income on products already licensed — SKVI should be profitable in 2010.

SKVI continues to work on other new licensing opportunities as well — success breeds success.

RHEI Pharmaceuticals HK Ltd. is a Hong Kong based pharmaceutical company and a subsidiary of Luxembourg-based Leeward Ventures SICAR SCA.

Profitability is the beginning of very good things for SKVI and its shareholders. This is a keeper.

Let’s all keep watching this one!

VIEW THE SKINVISIBLE PROFILE

Skinvisible, Inc. / Skinvisible Pharmaceuticals, Inc.
6320 S. Sandhill Road, Suite 10
Las Vegas, Nevada, 89120 U.S.A.
Phone:
702.433.7154
Fax:
702.433.7192
Email:
info@skinvisible.com
Phone:
801.485.7978
Fax:
801.466.6877

About Invisicare: Invisicare is Skinvisible’s patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash off and perspiration. Invisicare can control the release of actives, reduce irritation and can eliminate some costly manufacturing processes. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants. www.invisicare.com

About Skinvisible Pharmaceuticals, Inc.

Skinvisible is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing irritation. Skinvisible receives a combination of research and development fees, license fees, and royalties for the life of the patent. Skinvisible’s value also lies in its ability to continually generate new IP on topical products formulated with Invisicare.

Pentony Enterprises LLC is STOCKGURU.COM. 1601 Berwick Drive, McKinney, Texas 75070 – (469) 252-3030. Disclosure: StockGuru entered into an investor relations consulting and market awareness contract on July 12, 2010. The company has agreed to pay us five thousand dollars per month in cash for the period of six months, totaling thirty thousand USD. StockGuru was previously compensated 500,000 144 restricted common shares by the company for profile coverage for the period ending January 30, 2010. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. To further clarify, we will not be buying or selling shares for the period of July 12, 2010 through January 12, 2011. We hold no shares and will not be receiving further compensation that is share related during this period. Pentony Enterprises is not a registered investment adviser or a broker/dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Logo Header Menu